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Sulphonylureas (SU) were discovered in 1942 when French researchers observed severe hypoglycaemia in 
patients receiving sulphonamide treatment for typhoid fever 1. It was recognised that sulphonamide-
induced hypoglycaemia mimicked the action of insulin 2 3.  SU were introduced to clinical practice in the 
1950s.  
The last 10 years have seen major advances in type 2 diabetes mellitus (T2DM) pharmacotherapy 4  5 6. 
Such are these advances, that debate has been provoked that SU are no longer a justified second line 
therapy due to their inconsistent CV and mortality data 7 8, risks of hypoglycaemia, weight gain and 
secondary failure 9 10. By 2013, SU prescribing as add-on to metformin had fallen to 41.4% (95% CI 41.1% to 
41.7%) 11 with new favour towards DPP-IV inhibitors. Notably, this was before prescribing prevalence of 
GLP1-RA and SGLT-2 inhibitors started to increase 12 13.   
The controversies regarding whether SUs should continue to be used second line in T2DM treatment have 
been heavily debated 14, including at The American Diabetes Association annual scientific sessions in 2015 
15 16 . It is hoped that the results of the CAROLINA cardiovascular outcome trial (CVOT) of linagliptin vs 
glimepiride, expected in 2019, will resolve some of the debated issues 17. 
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This article explores the beta-cell physiology underpinning mechanisms of action of SUs, examines their 
evidence base, and seeks answers for concerns over their place in modern-day practice. Do they have 
potential for re-branding? With insights into SU physiology, pharmacogenetics and CVOT, are some SUs 
more favourable then others? 
 
Reflections on Beta Cell Physiology & Sulphonylurea Pharmacokinetics 
Several SU were available by the 1960s and were classified into two “generations”. First generation SU 
such as tolbutamide and chlorpropamide are now rarely used. Second generation SUs such as gliclazide 
(unavailable in USA), glipizide, glibenclamide (aka. glyburide) and glimepiride, are now some of the most 
widely prescribed drugs for T2DM (Table 1).  
SU were identified to cause beta-cell depolarisation in the 1960s 18, it was later noted that this was due to 
a decrease in the potassium permeability of the beta-cell membrane 19. Patch clamp electrophysiology 
studies found SU interact with, and close ATP-sensitive potassium (KATP) channels 
20. KATP channel closure 
decreases the permeability of the beta-cell membrane to potassium ions, which depolarises the membrane 
21.   
SU, unlike glucose, inhibit the KATP channel directly, causing depolarisation through Ca
2 influx, resulting in 
glucose-independent insulin secretion 22. Importantly, this differentiates SU from newer therapies (GLP-
1RA and DPP4i) that work in a glucose-dependent manner. Along with this “first phase” of insulin 
secretion, SU also induce the later “second phase” of insulin secretion to induce continuous formation of 
insulin granules 23.  
The KATP channel consists of four sulphonylurea receptors (SUR) surrounding four pore-forming Kir6.x 
subunits, which belong to the ATP-binding cassette transporter family and were cloned in the late 1990s 
and early 2000s 24. SUR are made up of 17 transmembrane helices and two intracellular nucleotide-binding 
domains for ATP-binding and hydrolysis 24.  
Tissue-specific KATP channels subunits are coded by different genes, which translate to Kir 6.1 and 6.2 
protein subunits 25. In addition, channel tissue variation is provided by alteration in the combination of 
Kir6.x and SUR subunits: pancreatic beta-cells carry Kir6.2/SUR1, cardiac muscle Kir6.2/SUR2A and SUR2B 
with either Kir6.1 or Kir6.2 is present in vascular smooth muscle 26 27.  
Gribble, Ashcroft and colleagues identified in Xenopus oocytes that the binding sites for SU with KATP 
channels are found on the SUR subunits, therefore different SU types will interact with the different KATP 
channels with different affinity 28 29 30 31.   The dose-response curve for SUR1 and SUR2 shows high and low 
affinity components of inhibition 29. Gliclazide, glipizide, tolbutamide and mitiglinide inhibit Kir6.2/SUR1 
with high affinity, but low affinity for Kir6.2/SUR232. (Table 1) Whereas glibenclamide, glimepriride, 
meglitinide, and repaglinide block both Kir6.2/SUR1 and Kir6.2/SUR2 with high affinity 28 31. Binding 
inhibition by gliclazide, glimepiride and repaglinide to Kir6.2/SUR1 is rapidly reversible, unlike 
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glibenclamide, glimepiride and meglitinide to Kir6.2/SUR2 33. Subunit binding affinity and reversibility may 
therefore be crucial when addressing SU efficacy, failure and CV safety.  
 
Could Insight from Sulphonylurea Studies in Neonatal Diabetes be Extrapolated to T2DM? 
Studies in neonatal diabetes (NDM) have provided insight into KATP channel physiology, as approximately 
50% of cases are caused by activating mutations in Kir6.2 (KCNJ11) or SUR1 (ABCC8) 34 35 36. These 
mutations reduce the ability of ATP to close the KATP channel 
35, thus prevent glucose-induced 
depolarisation and insulin release.  
NDM management advanced following a pharmacogenetic study of patients with Kir6.2 mutations. Of the 
49 participants, 44 successfully switched from insulin to a high dose SU 37. Switch was achieved with no 
episodes of severe hypoglycaemia, no increase in mild-to-moderate hypoglycaemia and was regardless of 
SU used 37. 
Physiological studies undertaken, before- and after introduction of SU in patients with activating KATP 
channel mutations were striking (Figure 1).  Patients had no insulin secretory response to I.V. glucose or 
glucagon before transition off insulin. However, following established SU use, there was a large insulin 
secretory response to glucagon. Similarly, in SU patients, insulin secretion following an oral glucose or 
mixed meal stimulus was much greater than seen with IV glucose.   
These results demonstrate that in patients with Kir6.2 mutations, the glycaemic benefit of SU resulting in 
near normoglycaemia and insulin cessation, is not due to a direct stimulatory effect of SU on insulin 
secretion, but due to SU raising the resting membrane potential of beta-cells to enable amplifying 
pathways to operate.  Most patients with NDM have an HbA1c close to or within the non-diabetic range 
yet do not have hypoglycaemia, consistent with the SU treatment in these patients enabling glucose 
stimulated insulin secretion.   
 
Could these insights be extrapolated to T2DM? NDM is a purely beta-cell disease, whereas T2DM 
physiology is multifactorial, influenced by insulin resistance, hyperglucagonaemia and impaired incretin 
effect. However, variants in SUR1 are also noted in adult diabetes; some present with impaired glucose 
tolerance, others with maturity-onset diabetes of the young (MODY), and others with T2DM 38 39.   A 40% 
reduction in glucose-stimulated insulin secretion (GSIS) in people with normal glucose tolerance is seen 
with a common variant of Kir6.2 (E23K) 34 40; this mutation is associated with increased risk of T2DM.  It is 
debated whether Kir6.2 (E23K) causes a reduction in ATP-inhibition 41 40. Others postulate that the 
polymorphism in SUR1 (A1369S), which is linked to Kir6.2 (E23K) drives lower ATP-sensitivity 42.  Therefore, 
for at least some patients with diabetes, KATP channel dysfunction contributes to their diabetes aetiology, 
and these patients may have a relatively hyperpolarised beta-cell.  The parallels here with NDM are 
apparent, suggesting that an appropriate dose of SU may promote GSIS with minimal hypoglycaemia. 
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Is There a Role for Low Dose Sulphonylureas? 
Henquin described a “sigmoidal hierarchy” between two pathways of GSIS 43 . Firstly, in the 
direct/triggering pathway whereby SU bind to SUR of the KATP channel and bring about channel closure. 
This stimulates insulin secretion and in-vitro stimulates insulin secretion in a glucose-independent 
mechanism. Secondly, the amplifying/potentiating pathway, in which incretin hormones (GLP-1/GIP), 
glucagon or arginine act to augment insulin secretion via a rise in cyclic AMP 43.  
 
In patients with T2DM, as is clearly seen in any study of conventional therapeutic dose of SU, this insulin 
secretion is not entirely glucose-regulated and there is a risk of hypoglycaemia. One can hypothesise that a 
low dose SU should potentiate beta-cell insulin secretion in a glucose-dependent mechanism. If true, their 
effect would raise the beta-cell membrane potential and, through “sigmoidal hierarchy”, allow activation 
of the amplifying pathway by glucagon and incretin hormones.  
 
A study of an isolated rat pancreas showed that gliclazide at concentrations 1/10th of those deemed 
therapeutic (0.25mcg/ml) potentiated GSIS, without increasing fasting insulin 44. Similarly, a study on just 
20mcg/kg body weight of glibenclamide in normoglycemic patients had no effect on fasting insulin 
secretion 45 . Thus, if a suitably low dose is given, then partial KATP channel closure will result, the amplifying 
pathway will be augmented, and GSIS will occur. Interestingly, in a study of single dose vildagliptin and 
5mg glibenclamide, the insulin secretion was increased following oral glucose but there was no greater risk 
of hypoglycaemia, consistent with glucose regulation of the combined treatment in this study where the 
OGTT was done just 30 minutes after the glibenclamide dose (i.e. concentrations would have been sub-
therapeutic) 46.  
 
Studies suggest that there is minimal glycaemic benefit of successive dose-escalation of SU. A prospective, 
case-controlled dose-escalation study of gliclazide assessed the relationship between dose and fasting and 
post-prandial glucose 47. In 13 patients, dose-escalation from 40mg to 80mg daily was associated with a 
significant change in mean blood glucose (mean [SD, 11.3 [4.2] vs 10.0 [3.9] mmol/L (p<0.001)) but not 
post-prandial excursion. Further dose-escalation from 80 to 160mg was not associated with additional 
clinical benefit. Significant change was only observed in 6hr post-prandial blood glucose (9.5 [4.2] vs 10.3 
[4.1] mmol/L [171.1 (75.7) vs 185.6 (73.9) mg/Dl]; p=0.018).  
 
Stenman et al drew similar conclusions: increasing the dose of glipizide to more than 10mg daily showed 
little glycaemic benefit in a cohort of 23 patients 48. Patients were given glipizide in three different dose 
schedules (10mg once or twice daily or 20mg twice daily), observing that mean blood glucose on home-
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monitoring was 12.4mmol/L during placebo versus 9.6, 9.2 and 8.9mmol/L respectively. The insulin 
response to a meal test was greatest after 10mg glipizide and weakest after 40mg (P = 0.02).  
 
Slow release formulations of glipizide and gliclazide result in lower, more sustained concentrations of 
sulphonylureas.  For example, standard release glipizide has a statistically higher Cmax of 1003 ng/ml lasting 
1 – 8 hours, and may be given twice daily, whereas extended-release glipizide has a Cmax of 499ng/ml 
lasting 6 – 12 hours 49 50.   In keeping with our hypothesis that lower dosing of sulphonylureas may be 
beneficial by enabling incretin action with minimal insulin secretion, modified-release gliclazide or glipizide 
are associated with low hypoglycaemic risk versus their short acting preparations such as 
glibenclamide/glyburide Error! Bookmark not defined. or glimepiride 51, or the difference in SU-associated weight 
gain, and faster time-to-failure with glibenclamide (Cmax 97.2 -105 ng/ml after 2 hours
52 ) than 
chlorpropamide (Cmax 22.7 – 26.8ug/ml sustained from 3 hours)
 53. 
 
What is the mechanism of sulphonylurea failure?  Are some sulphonylureas better than others? 
Concern was raised as to the numbers of patients progressing to additional therapy following long-term SU 
treatment 54. Although UKPDS did not show more rapid failure with SU compared to metformin , the 
ADOPT study does suggest that SU fail quicker than metformin and rosiglitazone 10. Kaplan–Meier analysis 
showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with 
metformin, and 34% with glyburide. Notably, the ADOPT study assessed newly-diagnosed diabetics, with 
more residual beta cell function than established T2DM. Progression-to-failure may be provoked by SU-
associated weight gain and fear of hypoglycaemia, leading to non-compliance, however several hypotheses 
exist for the molecular mechanism of failure.  
 
Firstly, persistent SU closure of the KATP channels may result in beta-cell apoptosis; this was investigated in 
cultured human islets 55. Glibenclamide (0.1 and 10 micromol) exposure for 4 hours induced 2.09- and 
2.46- fold increase in beta-cell apoptosis. Repaglinide (0.01 and 1 micromol) exposure produced no change 
in beta-cell apoptosis. Low dose nateglinide (10micromol) did not induce beta-cell apoptosis, however a 
1.49 increase in apoptosis was seen with higher concentration (1000 micromol).  
 
Another hypothesis is that persistent closure of the KATP channels results in insulin secretory failure without 
beta-cell death.  Slow-release glibenclamide pellets were implanted into wild-type mice to induce chronic 
KATP channel closure. The mice became progressively and persistently diabetic, with reduced insulin 
secretion in response to hyperglycaemia (p<0.05). Within 1 week of treatment, wild-type mice had 
developed almost the same degree of glucose intolerance as KATP knockout mice.  Interestingly, secretory 
capacity of wild-type mouse islets was restored within hours of glibenclamide washout, and in-vivo within This article is protected by copyright. All rights reserved.
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1 month after treatment termination. Immunostaining showed normal islet size and alpha/beta cell 
distribution within the islet, and no evidence of apoptosis. This study may give insight into secondary 
failure of SU treatment in humans with T2DM. Further studies are required, for example assessing whether 
insulin secretion can be restored after a SU treatment break. 
 
Initial SU response and subsequent failure is highly variable.  The UK Prospective Diabetes Study Group 
(UKPDS) examined SU failure in non-insulin dependent diabetic patients over 6 years 56. They prospectively 
followed newly-diagnosed T2DM (n=1305) randomly allocated to chlorpropamide or glibenclamide. By 6 
years, 44% had required additional therapy; 48% of those allocated to glibenclamide and 40% on 
chlorpropamide (p<0.01).  Modelling of beta-cell function concluded those with lower function were more 
likely to fail (p<0.0001). SU failure rate was dependent on the phenotype at presentation; higher glucose 
concentrations at initial presentation, younger age of presentation, lower residual beta cell reserve and 
BMI <30. 
 
Gliclazide was shown to cause less secondary beta cell failure than glibenclamide/glyburide (P<0.001) 57. 
This could be explained by its reversible binding to the KATP channel, and therefore it may not hyper-excite 
and exhaust beta-cells to the same degree as glibenclamide. There are three other potential explanations 
for this. The first relates anti-oxidant activity; that gliclazide has potent free radical-scavenging activity 
mediated by an azabicyclo-octyl ring on the SU core 58. The second is that chronic hyperglycaemia may 
induce oxidative stress, reduction in beta cell mass and tissue damage 59. Hyperglycaemia induces 
mitochondrial superoxide production, activating the uncoupling of protein 2, decreasing the ATP:ADP, 
producing an overall reduction in insulin secretion 60. 
 
Harrower concluded that gliclazide is the most potent SU with the lowest incidence of hypoglycaemia and 
reduced secondary failure rates 61 62. He compared T2DM (n=112) concurrently treated with different SU 
for 1 year (chlorpropamide, glipizide, gliquidone, glibenclamide (glyburide) or gliclazide). Gliclazide and 
glibenclamide achieved best results in terms of normalisation of HbA1c (80% and 74% respectively). 
Secondary failure rates were analysed in T2DM (n=248) treated for 5 years with gliclazide, glibenclamide or 
glipizide. Gliclazide had the lowest secondary failure rate (7% in 5 years) and was significantly better than 
glipizide (25.6%) and just below significant threshold in comparison to glibenclamide (17.9%) 62. In 
alternative methodology, UKPDS utilised a “coefficient of failure” chlorpropamide patients showed a mean 
COF of 0.34 HbA1c%/year (0.44%/year SD) and glibenclamide-treated patients 0.50 HbA1c%/year 
(0.50%/year SD) (p=0.046; unpaired two-tailed t-test) 63.   
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Can precision medicine modernise how we use sulphonylureas? 
Pharmacogenetic variants have been associated with SU response or failure.  In the KATP channel, Feng et al 
identified an association between carriers of risk A allele at Ala1369Ser of the ATP-binding cassette 
subfamily member gene ABCC8 (who have lower insulin secretory function) 64, who had a greater decrease 
in fasting plasma glucose (FPG) and HbA1c after 8 weeks treatment with gliclazide.  The GoDARTS study 
reported that loss-of-function CYP2C9 variants improve therapeutic response to SU in T2DM and were 
associated with less SU failure 65. Incident users of SU in Tayside (n=1073) were assessed for the impact of 
the combined CYP2C9*2 and CYP2C9*3 genotypes on early and sustained SU response. Patients with two 
copies of a loss-of-function allele were 3.4 times (P = 0.0009) more likely to achieve a treatment HbA1c 
level <7% than patients with two wild-type CYP2C9 alleles. This was noted to correspond with a 0.5% (P = 
0.003) greater reduction in HbA1c. As mentioned, *2 and *3 allele carriers were less likely to experience 
treatment failure with SU monotherapy (P = 0.04; per-allele HR 0.79; 95% CI 0.63-0.99).  Further studies 
are required to evaluate whether genotype at CYP2C9 or ABCC8 can be used to improve outcomes of 
patients treated with sulphonylureas. 
 
Sulphonylurea Efficacy and Safety 
There is no doubt that SU are effective, both in terms of initial HbA1c reduction and cost. A systematic 
review and meta-analysis of SU efficacy on HbA1c reduction, evaluated 31 trials with a median duration of 
16 weeks 66 . SU monotherapy lowered HbA1c by 1.51% (17mmol/mol) more than placebo (95% CI 1.25, 
1.78) (Figure 2). SU added to oral diabetes treatment lowered HbA1c by 1.62% (18mmol/mol; 95% CI 1.0, 
2.24) compared with other therapy and SU added to insulin lowered HbA1c by 0.46% (6mmol/mol; 95% CI 
0.24, 0.69) and lowered insulin dose. Higher SU doses did not produce any greater HbA1c reduction than 
lower doses. SU treatment resulted in more hypoglycaemic events (RR 2.41, 95% CI 1.41, 4.10) but did not 
significantly affect the number of adverse events. The ADOPT study compared SU versus metformin and 
rosiglitazone; SU showed greater HbA1C reduction in the first 6 months of treatment 10. However, SU 
treatment failure was the highest versus comparators by end of study 67. A recent re-analysis of the ADOPT 
study by the MASTERMIND consortium showed how SU were much more effective than Rosiglitazone in 
non-obese men. In contrast, obese women responded better over 5 years to Rosiglitazone than SU 68.  
 
A large meta-analysis addressed gliclazide efficacy and safety 69, T2DM patients treated with gliclazide 
(n=3083) versus other OHA (n=3155) of at least 12-weeks duration were included. Outcomes were HbA1c 
change, severe hypoglycaemia incidence, weight change and mortality. Gliclazide was slightly more 
effective versus other OHA, apart from metformin (-0.13% (95% CI: -0.25, -0.02, I2 55%)). One out of 2387 
gliclazide patients experienced a severe hypoglycaemic event, whilst concomitantly on insulin. There were 
25 non-severe hypoglycaemic events (2.2%) in 1152 gliclazide users and 22 events (1.8%) in 1163 users in 
the comparator group (risk ratio 1.09 (95% CI: 0.20, 5.78, I2 77%)).  This article is protected by copyright. All rights reserved.
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 A large Canadian multi-centre study (n=114 sites) found gliclazide to be safe, well tolerated and efficacious 
in most patients studied 70.  Gliclazide (80mg – 320mg daily) was given for three months T2DM patients 
(n=411) sub-optimally controlled with diet or monotherapy. A significant reduction was seen in fasting, 2-
hour and HbA1c levels compared with baseline (P = 0.01). Adverse events, aside from hypoglycaemia, were 
recorded in 7.3% of patients and led to withdrawal of 1.2% of patients from study. Hypoglycaemic events 
were less frequently encountered than with previous monotherapy (P = 0.001). However, it is important to 
note that severe hypoglycaemic events requiring medical attention compose a small fraction compared 
with the number of severe hypoglycaemic events requiring third-party assistance in community, or mild-
moderate lows, the majority of which go undocumented.   
 
 
The ongoing Glycaemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) 
compares SU (glimepiride) to other contemporary 2nd line treatment 2nd line treatment (sitagliptin, 
liraglutide or basal insulin) in 5047 patients for up to 7 years. Hopefully this study will establish the position 
of sulphonylureas relative to other second line treatments.  However, it should be noted that SGLT-2 
inhibitors, now commonplace 2nd line therapy with excellent outcome data, are not included in this 
analysis. The primary outcome is time to primary failure (HbA1c ≥7%) while receiving metformin (up to 
2000mg per day) and the randomly assigned study medication by intention-to-treat. The secondary 
outcome is time to secondary failure (HbA1c>7.5%). GRADE will record other attributes such as CV disease, 
safety, tolerability and cost-effectiveness, however it is not powered as a clinical outcomes study.  
 
Exploring Sulphonylurea Cardiovascular Safety 
Sulphonylureas have  chequered cardiovascular outcomes, however, it is important to note that many 
early conclusions were derived from studies which were not originally powered to evaluate these 
outcomes. Thus, the detrimental results of studies may have been overstated. It is hoped that the results 
of CAROLINA CVOT which reports in 2019 and compares linagliptin with glimepiride will establish once and 
for all whether sulphonylureas (albeit glimepiride only) increase CV risk 17; this follows on from CARMELINA 
CVOT which established the  CV safety of linagliptin versus placebo 71.   
 
In the 1970s, the University Group Diabetes Program (UGDP) was the one of the first randomised trials in 
diabetes 72 73 74. Patients (n=200) were randomised to insulin, tolbutamide or placebo (a phenformin arm 
was later added). The tolbutamide arm was stopped prematurely due to increased death rate (12.7% vs. 
4.9% in the placebo group) causing the FDA to issue a black-box warning against SU 75. Of note, 
tolbutamide also displayed increased risk of CV events compared with insulin therapy, which also causes 
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hypoglycaemia. However, UDGP design and conduct are still disputed, as the tolbutamide cohort had 
increased CV events by the study outset 76.  
 
The UKPDS provided clearer guidance 77 observing that reducing glucose exposure (HbA1c 7.0% versus 
7.9% over median 10.0 years), with SU or insulin therapy, reduced the risk of “any diabetes related 
endpoint” by 12% and microvascular disease by 25%, with a 16% trend to a reduced risk of myocardial 
infarction (MI) (P=0.052). UKPDS displayed no increase in CV death, MI or sudden death with SU use. 
However, the study was not powered to evaluate these outcomes.  
 
The TOSCA.IT primary prevention trial also provided reassuring evidence for CV safety of SU 78, having 
compared long-term CV outcomes of two widely used, and affordable drugs in T2DM. Patients were 
randomised to pioglitazone (n=1535) or SU (=1493) (2% glibenclamide, 48% glimepiride, 50% gliclazide), 
11% of participants had documented previous MACE prior to study start. The trial was stopped early on 
basis of futility analysis after median follow up of 57.3 months. Data showed SU to have similar CV event 
incidence to pioglitazone as add-on to metformin. The primary outcome of composite first occurrence of 
all-cause death, non-fatal MI, non-fatal stroke or urgent coronary revascularisation was observed in n=105 
(1.5 per 100 person-years) in the pioglitazone group, versus n= 1 08 (1.5 per 100 person-years) on SU (HR 
0.96, 95% CI 0.74-1.26, p=0.79). SU had increased reported hypoglycaemia than pioglitazone (508 (34%) vs 
148 (10%), p<0.0001).  The PROACTIVE study showed that pioglitazone reduced CV events (main secondary 
endpoint of all-cause mortality, non-fatal MI, and stroke) compared to placebo, the finding that patients 
randomised to SU had similar CV outcomes to those treated with pioglitazone in TOSCA.IT does suggest 
that SU do not increase CV events. However, it should be noted that PROACTIVE study was again not 
powered to assess CV safety as a primary endpoint and recruited a cohort of patients with established CV 
disease or high CV risk.  
 
Large meta-analyses report inconsistent findings on SU CV safety, these can be divided into meta-analyses 
of randomised controlled trials (RCT), and meta-analyses of observational data 79 80 81. A Cochrane meta-
analysis of 72 RCT assessed the effects of SU monotherapy (n=9707) versus placebo, no intervention or 
other OHA (n=12,805). No significant association was found between SU and mortality versus metformin 
monotherapy (pooled RR 1.47, 95% CI 0.54 – 4.01). The meta-analysis showed that the impact of SU on CV 
safety may not be a class effect; first generation sulphonylureas were associated with increased CV 
mortality compared to placebo (RR 2.63, 95% CI 1.32 – 5.22, p = 0.006), whereas no difference was found 
with second generation sulphonylureas.  It should be noted that none of the studies were powered to 
detect CV events81. 
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Observational studies tend to report increased CV risk for SU versus comparator (often metformin). It is 
difficult to draw conclusions from observational studies as there is scope for considerable bias, even after 
rigorous methods to account for this.   
 
Does Tissue Specificity of Sulphonylureas Affect Cardiovascular Safety? 
A recent study used genetic variation in SUR to predict the causal association of KATP channel closure 
(mimicking SU action) on CHD outcomes82, the results are summarised in Figure 3. In 120,286 UK Biobank 
participants, the p.A1369S SUR1 variant described earlier was associated with a significantly lower risk of 
T2DM (odds ratio (OR) 0.93; 95% CI 0.91, 0.95; P=1.2 x 10-11). Importantly, pA1369 was associated with a 
reduced risk of CV disease (OR 0.98; 95% CI 0.96, 0.99; P = 5.9 x 10-4). The variant was associated with 
increased BMI (+0.062 kg/m2; 95% CI 0.037, 0.086; P = 8.1 x 10-7) but lower waist-to-hip ratio adjusted for 
BMI. The data emphasises that SU may reduce the risk of CV disease, despite their association with weight 
gain.  
In the SPREAD DIMCAD study, first generation sulphonylureas were associated with increased CV events. 
This may be due their lower affinity for pancreatic beta-cell SUR1, but higher affinity for cardiac and 
vascular smooth muscle SUR2 which may interfere with ischaemic cardiac pre-conditioning 83. Second 
generation SU have an affinity for SUR1 with no effect on cardiac or vascular smooth muscle SU receptors 
84 85, which upholds the findings of Gribble et al. 31. Non-selective blockade of myocardial SUR receptors 
worsens post-ischaemic wall function by shortening the action potential 86 87 88.  
 
A meta-analysis and systematic review addressed tissue-selectivity and mortality risk among SU 89 
observing that gliclazide and glimepiride were associated with a lower risk of all-cause and CV-related 
mortality compared with glibenclamide. In contrast, a series of retrospective analyses by Pantalone et al 90 
obs rved increased mortality risk of SU (glipizide, glyburide/glibenclamide, glimepiride) versus 
metformin 91 . Further analysis did not identify increased mortality risk among the different SU 
combinations and metformin 92 In an additional retrospective analysis of the same SU as monotherapy, 
there was no increased mortality risk between individual SU however, glimepiride was the preferred SU in 
those with underlying CAD 93. It should be noted that as this retrospective analysis was conducted in the 
USA, gliclazide was not part of the analysis.   It should also be noted in contrast to gliclazide, that 
glimepiride is not pancreatic SUR selective (Table 1). 
 
A retrospective cohort study (n=14,213) assessing the dose-response relationship between gliclazide, 
glibenclamide (glyburide) and MACE, demonstrated once again that low dose SU is better than high dose 
SU, and that SUs with pancreatic specificity are better than those without94. MACE was higher in both high-
dose gliclazide and glibenclamide versus low-dose (gliclazide crude rates: 32.8 and 28.2 per 1000 person-
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years, 1.15; 95% CI (0.96-1.38), glibenclamide crude rates: 38.9 and 31.5 per 1000 person-years; HR 1.24; 
95% confidence interval 1.02-1.50)) (Figure 4).  Furthermore, in patients who have had a myocardial 
infarction, Glibenclamide (glyburide) binding to SUR on cardiac myocytes may result in increased infarct 
size and reduced LV function 95. This was similarly demonstrated in rat models comparing glibenclamide 
with gliclazide on myocardial infarct size 95. Glibenclamide, but not gliclazide, was noted to exacerbate 
ischaemic/reperfusion injury along with associated with deterioration in LV function post-MI in diabetic 
hearts.  
 
Conclusion 
Since the accidental discovery of the hypoglycaemic effect of sulphonamides over 60 years ago, SU have 
become a stalwart of T2DM management. Despite the increasing therapeutic options, SU still have an 
important role to play in glucose lowering therapy.  We have highlighted how the concerns regarding 
hypoglycaemia, secondary failure and cardiovascular safety are over-stated.  Especially when one considers 
the data for gliclazide rather than non-selective SU such as glibenclamide. As shown, the evidence not only 
suggests that gliclazide has efficacy in terms of glycaemic control 55, lower secondary failure rates 49, and is 
equivalent to pioglitazone in terms of incidence of CV events in the TOSCA.IT study 69. Glipizide is probably 
the most selective SU and should be considered. However, as CV outcomes for glipizide are not well 
reported, evidence does not point to a clear alternative in the absence of gliclazide 96.  
 
We believe that the issues of hypoglycaemia and secondary failure may be minimised by considering the 
physiological action of SU, the insights gained from the treatment of patients with NDM, and the beneficial 
outcomes of slow release lower dose preparations of SU. These data suggest that SU are used in too high a 
dose, and lower doses of SU may be only slightly less effective yet have reduced risk of SU and secondary 
failure.  With research into these areas it may be possible to modernise the use of this old drug class and 
prevent a useful drug class in the management of diabetes falling from use. 
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Figure Legends 
Table 1. Summary of Commonly Used Sulphonylureas, SUR Affinity and Pharmacokinetics  
 
Figure 1. Physiological Studies of the Effect of Associated Mechanisms of Sulfonylurea Treatment on Insulin Secretion 
Panel A shows the median incremental increase in insulin concentration above baseline in an intravenous glucose-tolerance test 
(16 patients) and an oral glucose-tolerance test (5 patients) before treatment was switched from insulin to sulfonylureas (blue 
lines) and after treatment (black lines).  
Panel B shows the median incremental increase in insulin and glucose concentration from baseline in response to intravenous 
glucose, oral glucose and mixed meal in seven patients whose treatment was successfully switched from insulin to sulfonylurea.  
Panel C shows median concentration of total glucagon-like peptide 1 (GLP1) (blue lines) and the median incremental increase in 
insulin concentration above baseline (red lines) in response to an oral glucose-tolerance test in four patients before and after 
treatment was switched to sulphonylurea. 
Panel D shows the median incremental increase in insulin concentration above baseline after glucagon stimulation in five. 
 
Figure 2. Reproduced from Hirst et al, Estimating the effect of sulphonylurea on HbA1c in diabetes: a systematic 
review and meta-analysis. Diabetologia May 2013, 56(5) pp973-984.  Mean difference in change in HbA1c of 
sulfonylurea monotherapy treatment vs placebo (boxes) and pooled estimates (diamonds) calculated by the random 
effects DerSimonian and Laird method. Horizontal bars and diamond widths denote 95% CIs and box sizes indicate 
relative weight in the analysis.  
Permission Required Prior to Publication 
 
Figure 3. Reproduced from Emdin et al. Genetic Variation at the Sulphonylurea Receptor, Type 2 Diabetes and Coronary Heart 
Disease. Diabetes. 2017 Aug;66(8)2310-2315 
Permission Required Prior to Publication 
a) Association of ABCC* p.A1369S with Type 2 Diabetes and Coronary Heart Disease 
b) Association of ABCC8 p.A1369S with Cardiometabolic Traits 
c) Association of ABCC8 p.A1369S with Cardiovascular Disease 
 
Figure 4. Hazard ratios (HR) for major adverse cardiovascular events among new users of gliclazide and glyburide 
Adapted from Ahmed S, Abdelmoneim et al. Dose response relationship between sulfonylureas and major adverse 
cardiovascular events in elderly patients with type 2 diabetes. Pharmacoepidemiology and Drug Safety. 2016 Oct;25 (10):1186 – 
1195.  
Permission Required Prior to Publication. 
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Table 1 – Commonly Used Sulphonylureas, SUR Affinity and Pharmacokinetics 97 98 99 
 
Sulphonylurea Trade Name Dose 
Range 
SUR  
High 
Affinity 
SUR  
Low 
Affinity 
Onset Peak 
Concentration 
T ½ 
Plasma 
First Generation 
Tolbutamide Tolbutamide 0.5 – 2g 
Daily 
Kir6.2/SUR1 Kir6.2/SUR2 1 Hour Serum: 3-4 Hours 4 – 25 
Hours 
Chlorpropamide Diabinese 100 – 
750mg 
Daily 
Kir6.1/SUR1 
Kir6.2/SUR2 
 1 Hour Effect: 3 – 6 
Hours 
Serum: 2-3 Hours 
36 
Hours 
Tolazamide Tolazamide 100mg – 
1000mg 
Daily 
Kir6.2/SUR1 Kir6.2/SUR2 20 
Minutes 
Effect: 4-6 Hours 
Serum: 3-4 Hours 
7Hours 
Second Generation 
Glibenclamide/ 
Glyburide 
Daonil 5 – 15mg 
Daily 
Kir6.1/SUR1 
Kir6.2/SUR2 
 15 – 60 
Minutes 
Serum: 2-4 Hours 10 
Hours  
Gliclazide 
(Not available in 
USA) 
Diamicron 
 
Diamicron MR 
(Modified 
Release) 
40 – 
320mg 
Daily 
 
30 – 
120mg 
Daily 
Kir6.2/SUR1 Kir6.2/SUR2 1 Hour Serum: 1 – 8 
Hours 
 
Modified 
Release: 6 – 12 
Hours 
6 – 14 
Hours 
 
16 
Hours 
Glipizide Glibenese 
Minodiab 
 
 
Glucotrol XL 
2.5 – 
20mg 
Daily 
Kir6.2/SUR1 Kir6.2/SUR2 15 – 30 
Minutes 
Serum:  
Immediate 
Release 1-3 
Hours 
GITS/Sustained 
Release 6 – 12 
Hours 
2-5 
Hours 
 
 
 
15 
Hours 
Glimepiride Amaryl 1 – 6mg 
Daily 
Kir6.1/SUR1 
Kir6.2/SUR2 
 2 – 3 
Hours 
Serum:2-3 Hours 5 – 9 
Hours 
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Figure 1 
 
 
 
“From Ewan R. Pearson M.R.C.P, P.H.D et al. Switching from Insulin to Oral Sulfonylureas in Patients with 
Diabetes Due to Kir6.2 Mutations. New England Journal of Medicine 2006; Volume 355, Page 467 – 477”.  
Copyright © 2006 Massachusetts Medical Society. Reprinted with permission. 
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Figure 2 
 
Sulphonylurea Monotherapy Trials  
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Figure 3  
 
A) Association of ABCC8 p.A1369S with type 2 diabetes and coronary heart disease 
B) Association of ABCC8 p.A1369S with cardiometabolic traits 
 
C) Association of ABCC8 p.A1369S with cardiovascular disease 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Figure 4 
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